Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury

British Journal of Pharmacology

Volumn 174, Issue 14, 2017, Pages 2273-2286

  Reichetzeder, Christoph ^a,b   von Websky, Karoline ^a,b   Tsuprykov, Oleg ^a,b,h   Mohagheghi Samarin, Azadeh ^a,c   Falke, Luise Gabriele ^b   Dwi Putra, Sulistyo Emantoko ^a,e   Hasan, Ahmed Abdallah ^a,f   Antonenko, Viktoriia ^a,b   Curato, Caterina ^b,d   Rippmann, Jörg ^g   Klein, Thomas ^g   Hocher, Berthold ^a,h,i  

^a UNIVERSITY OF POTSDAM   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF SOUTH BOHEMIA   (Czech Republic)

^d DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^e UNIVERSITY OF SURABAYA   (Indonesia)

^f Zagazig University   (Egypt)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^h Campus Benjamin Franklin   (Germany)

ⁱ HUNAN NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATIN C; DIPEPTIDYL PEPTIDASE IV; GAMMA INTERFERON; GLUCAGON LIKE PEPTIDE 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LINAGLIPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; SITAGLIPTIN; TUMOR NECROSIS FACTOR; VILDAGLIPTIN; ADAMANTANE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DPP4 PROTEIN, RAT; NITRILE; PYRROLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; ENZYME ACTIVITY; ENZYME INHIBITION; HISTOPATHOLOGY; KIDNEY FUNCTION; KIDNEY ISCHEMIA; KIDNEY MASS; KIDNEY STRUCTURE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; KIDNEY; METABOLISM; PATHOLOGY; STRUCTURE ACTIVITY RELATION; WISTAR RAT;

ADAMANTANE; ANIMALS; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; KIDNEY; LINAGLIPTIN; MALE; MOLECULAR STRUCTURE; NITRILES; PYRROLIDINES; RATS; RATS, WISTAR; REPERFUSION INJURY; SITAGLIPTIN PHOSPHATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85020212494     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13822     Document Type: Article

References (64)

1. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
2. Arsenijevic D, Cajot J-F, Dulloo AG, Montani J-P (2015). Uninephrectomy in rats on a fixed food intake results in adipose tissue lipolysis implicating spleen cytokines. Front Physiol 6: 195.
3. Baetta R, Corsini A (2011). Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 71: 1441–1467.
4. Basile DP, Anderson MD, Sutton TA (2012). Pathophysiology of acute kidney injury. Compr Physiol 2: 1303–1353.
5. Belayev LY, Palevsky PM (2014). The link between acute kidney injury and chronic kidney disease. Curr Opin Nephrol Hypertens 23: 149–154.
6. Bloomfield DM, Krishna R, Hreniuk D, Hickey L, Ghosh K, Bergman AJ et al. (2009). A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects. J Clin Pharmacol 49: 937–946.
7. Blydt-Hansen TD, Katori M, Lassman C, Ke B, Coito AJ, Iyer S et al. (2003). Gene transfer-induced local heme oxygenase-1 overexpression protects rat kidney transplants from ischemia/reperfusion injury. J Am Soc Nephrol 14: 745–754.
8. Bonventre JV, Yang L (2011). Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 121: 4210–4221.
9. Ceriello A, Sportiello L, Rafaniello C, Rossi F (2014). DPP-4 inhibitors: pharmacological differences and their clinical implications. Expert Opin Drug Saf 13 (Suppl 1): S57–S68.
10. Chang M, Chen C, Chen Y, Wu Y, Zhen Y, Leu S et al. (2015). Sitagliptin protects rat kidneys from acute ischemia-reperfusion injury via upregulation of GLP-1 and GLP-1 receptors. Acta Pharmacol Sin 36: 119–130.
11. Chawla LS, Amdur RL, Amodeo S, Kimmel PL, Palant CE (2011). The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int 79: 1361–1369.
12. Chaykovska L, von Websky K, Rahnenführer J, Alter M, Heiden S, Fuchs H et al. (2011). Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS One 6: e27861.
13. Chen Y-T, Tsai T-H, Yang C-C, Sun C-K, Chang L-T, Chen H-H et al. (2013). Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. J Transl Med 11: 270.
14. Coca SG, Singanamala S, Parikh CR (2012). Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 81: 442–448.
15. Connelly KA, Bowskill BB, Advani SL, Thai K, Chen L-H, Kabir MG et al. (2014). Dipeptidyl peptidase-4 inhibition improves left ventricular function in chronic kidney disease. Clin Invest Med 37: E172.
16. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SPA, Giembycz MA et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461–3471.
17. Daniel C, Grigo C, Wang Z, von Hörsten S, Amann K (2012). CD26/DPP4 deficiency impairs kidney function in the ischemia/reperfusion model in the rat. Poster (P351) presented at: 4. Jahrestagung der Deutschen Gesellschaft für Nephrologie. 08.10.2012. Hamburg. Germany. Available at: http://www.aey-congresse.com/nephrokongress2012/Sitzung.aspx?PSID=1921&PAID=4866
18. Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT et al. (2011). Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17: 1481–1489.
19. Endre ZH, Kellum JA, Di Somma S, Doi K, Goldstein SL, Koyner JL et al. (2013). Differential diagnosis of AKI in clinical practice by functional and damage biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference. Contrib Nephrol 182: 30–44.
20. Field A (2013). Discovering Statistics Using IBM SPSS Statistics. SAGE: London, UK.
21. Filippatos TD, Athyros VG, Elisaf MS (2014). The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. Expert Opin Drug Metab Toxicol 10: 787–812.
22. Glorie LLF, Verhulst A, Matheeussen V, Baerts L, Magielse J, Hermans N et al. (2012). DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 303: F681–F688.
23. Hocher B, Sharkovska Y, Mark M, Klein T, Pfab T (2013). The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. Int J Cardiol 167: 87–93.
24. Hsu CY, Ordoñez JD, Chertow GM, Fan D, McCulloch CE, Go AS (2008). The risk of acute renal failure in patients with chronic kidney disease. Kidney Int 74: 101–107.
25. Huan Y, Jiang Q, Liu J, Shen Z (2015). Establishment of a dipeptidyl peptidases (DPP) 8/9 expressing cell model for evaluating the selectivity of DPP4 inhibitors. J Pharmacol Toxicol Methods 71: 8–12.
26. Jungraithmayr W, De Meester I, Matheeussen V, Baerts L, Arni S, Weder W (2012). CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation. Eur J Cardiothorac Surg 41: 1166–1173.
27. Kahles F, Meyer C, Möllmann J, Diebold S, Findeisen HM, Lebherz C et al. (2014). GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. Diabetes 63: 3221–3229.
28. Kam Tao Li P, Burdmann EA, Mehta RL (2013). Acute kidney injury: global health alert. J Nephropathol 2: 90–97.
29. Kellum JA (2015). Diagnostic criteria for acute kidney injury: present and future. Crit Care Clin 31: 621–632.
30. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577–1579.
31. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2012). Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. Osteoarthritis Cartilage 20: 256–260.
32. Kramann R, Kusaba T, Humphreys BD (2015). Who regenerates the kidney tubule? Nephrol Dial Transplant gfu281 30: 903–910.
33. Lafrance J-P, Miller DR (2010). Acute kidney injury associates with increased long-term mortality. JASN 21: 345–352.
34. McGrath JC, Lilley E (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189–3193.
35. Mentlein R (1999). Dipeptidyl-peptidase IV (CD26) – role in the inactivation of regulatory peptides. Regul Pept 85: 9–24.
36. Mulvihill EE, Drucker DJ (2014). Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev 35: 992–1019.
37. Muth JED (2014). Basic Statistics and Pharmaceutical Statistical Applications, Third edn. CRC Press: Boca Raton, FL, USA.
38. Nakamaru Y, Akahoshi F, Iijima H, Hisanaga N, Kume T (2016). Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase-4 inhibitors. Biopharm Drug Dispos 37: 142–155.
39. Nambi P, Gellai M, Wu HL, Prabhakar U (1997). Upregulation of osteopontin in ischemia-induced renal failure in rats: a role for ET-1? Biochem Biophys Res Commun 241: 212–214.
40. Noiri E, Dickman K, Miller F, Romanov G, Romanov VI, Shaw R et al. (1999). Reduced tolerance to acute renal ischemia in mice with a targeted disruption of the osteopontin gene. Kidney Int 56: 74–82.
41. Nuransoy A, Beytur A, Polat A, Samdanci E, Sagir M, Parlakpinar H (2015). Protective effect of sitagliptin against renal ischemia reperfusion injury in rats. Ren Fail 37: 687–693.
42. Padanilam BJ, Martin DR, Hammerman MR (1996). Insulin-like growth factor I-enhanced renal expression of osteopontin after acute ischemic injury in rats. Endocrinology 137: 2133–2140.
43. Park Y, Hirose R, Dang K, Xu F, Behrends M, Tan V et al. (2008). Increased severity of renal ischemia-reperfusion injury with venous clamping compared to arterial clamping in a rat model. Surgery 143: 243–251.
44. Persy VP, Verstrepen WA, Ysebaert DK, De Greef KE, De Broe ME (1999). Differences in osteopontin up-regulation between proximal and distal tubules after renal ischemia/reperfusion. Kidney Int 56: 601–611.
45. Persy VP, Verhulst A, Ysebaert DK, De Greef KE, De Broe ME (2003). Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice. Kidney Int 63: 543–553.
46. Putra SED, Tsuprykov O, Von Websky K, Ritter T, Reichetzeder C, Hocher B (2014). Dealing with large sample sizes: comparison of a new one spot dot blot method to western blot. Clin Lab 60: 1871–1877.
47. Racusen LC, Solez K (1986). Nephrotoxic tubular and interstitial lesions: morphology and classification. Toxicol Pathol 14: 45–57.
48. Sauvé M, Ban K, Momen MA, Zhou Y-Q, Henkelman RM, Husain M et al. (2010). Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 59: 1063–1073.
49. Scheen AJ (2015). Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet 54: 1–21.
50. Schnapp G, Klein T, Hoevels Y, Bakker RA, Nar H (2016). Comparative analysis of binding kinetics and thermodynamics of dipeptidyl peptidase-4 inhibitors and their relationship to structure. J Med Chem 59: 7466–7477.
51. Silver SA, Cardinal H, Colwell K, Burger D, Dickhout JG (2015). Acute kidney injury: preclinical innovations, challenges, and opportunities for translation. Can J Kidney Health Dis 2: 30.
52. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH et al. (2016). The IUPHAR/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 44: D1054–D1068.
53. Thakar CV, Christianson A, Freyberg R, Almenoff P, Render ML (2009). Incidence and outcomes of acute kidney injury in intensive care units: a veteran's administration study. Crit Care Med 37: 2552–2558.
54. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M (2008). (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 325: 175–182.
55. Timper K, Grisouard J, Sauter NS, Herzog-Radimerski T, Dembinski K, Peterli R et al. (2013). Glucose-dependent insulinotropic polypeptide induces cytokine expression, lipolysis, and insulin resistance in human adipocytes. Am J Physiol Endocrinol Metab 304: E1–13.
56. Timper K, Dalmas E, Dror E, Rütti S, Thienel C, Sauter NS et al. (2016). Glucose-dependent insulinotropic peptide stimulates glucagon-like peptide 1 production by pancreatic islets via interleukin 6, produced by α cells. Gastroenterology 151: 165–179.
57. Uchida S, Endou H (1988). Substrate specificity to maintain cellular ATP along the mouse nephron. Am J Physiol 255: F977–F983.
58. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S et al. (2005). Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294: 813–818.
59. Vaghasiya J, Sheth N, Bhalodia Y, Manek R (2011). Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes. Regul Pept 166: 48–54.
60. Vercauteren SR, Ysebaert DK, De Greef KE, Eyskens EJ, De Broe ME (1999). Chronic reduction in renal mass in the rat attenuates ischemia/reperfusion injury and does not impair tubular regeneration. J Am Soc Nephrol 10: 2551–2561.
61. Wagner M, Cadetg P, Ruf R, Mazzucchelli L, Ferrari P, Redaelli CA (2003). Heme oxygenase-1 attenuates ischemia/reperfusion-induced apoptosis and improves survival in rat renal allografts. Kidney Int 63: 1564–1573.
62. Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F (2001). Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int 60: 1645–1657.
63. Youssef MI, Mahmoud AAA, Abdelghany RH (2015). A new combination of sitagliptin and furosemide protects against remote myocardial injury induced by renal ischemia/reperfusion in rats. Biochem Pharmacol 96: 20–29.
64. Zhang Z-X, Shek K, Wang S, Huang X, Lau A, Yin Z et al. (2010). Osteopontin expressed in tubular epithelial cells regulates NK cell-mediated kidney ischemia reperfusion injury. J Immunol 185: 967–973.